

1 The Relationship Between Immune Cells and Heart Failure: A 2 Study Integrating Immune Infiltration Analysis and Bidirectional 3 Mendelian Randomization

4 Yiding Yu^{1#} Huajing Yuan^{1#} Wenwen Liu² Yitao Xue³ Xiujuan Liu³ Wangjun Hou¹ Yan
5 Li³

- 6 1. Shandong University of Traditional Chinese Medicine, Jinan 250014, China;
- 7 2. Traditional Chinese Medicine Hospital of Jimo District, Qingdao 266200, China;
- 8 3. Affiliated Hospital of Shandong University of Traditional Chinese Medicine,
9 Jinan 250014, China

10 #: These authors contributed to the work equally and should be regarded as co-first
11 authors.

12 **Correspondence:** Correspondence should be addressed to Wangjun Hou;
13 331438192@qq.com and Yan Li; liyan88130@163.com.

14
15
16 **Background:** In recent years, attempts have been made to employ various
17 immunomodulatory therapies as new treatment strategies for heart failure, yet the
18 outcomes have been disappointing. Consequently, unveiling the complexity and causal
19 relationships of the immune system's role in heart failure has become imperative.

20 **Methods:** We first determined the levels of immune cells in failing myocardium using
21 five immune infiltration algorithms: Cibersort, xCell, ssGSEA, MCPcounter, and
22 QuanTIseq. Subsequently, two-sample bidirectional Mendelian Randomization (MR)
23 analysis was conducted between heart failure and 731 immune cell phenotypes using
24 Inverse Variance Weighted (IVW) as the main method, reinforced by MR-Egger,
25 Weighted median, and Weighted mode as secondary analysis methods. Sensitivity
26 analyses were performed to ensure data stability and feasibility.

27 **Results:** Immune infiltration analysis revealed changes in the levels of immune cell
28 infiltration in failing myocardium, including T cells, Mast cells, B cells, NK cells, and

29 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
macrophages. MR analysis indicated that 19 immune cell phenotypes from 5 cell types

30 were associated with an increased risk of heart failure, while 12 immune cell
31 phenotypes from 6 cell types were associated with a decreased risk, without
32 heterogeneity and pleiotropy. Reverse MR analysis did not support a causal relationship
33 between HF and any of the 731 immune cell phenotypes.

34 Conclusion: Our study highlights the complex pattern and causal relationship between
35 the immune system and heart failure through immune infiltration and MR analyses.
36 This provides new insights for the exploration of immunocyte therapies for heart failure.

37 KEYWORDS: heart failure; immune cell phenotypes; Mendelian Randomization
38 analysis; immune infiltration analysis; Causally association

39


40 INTRODUCTION

41 Cardiovascular diseases are among the leading causes of mortality worldwide,
42 encompassing conditions such as hypertension, arrhythmias, coronary artery disease,
43 heart failure, and other heart-related diseases. Heart failure, in particular, often
44 represents the final stage of most cardiovascular diseases. It generally results from
45 structural modifications or functional disorders of the heart, leading to impairments in
46 ventricular filling or ejection capabilities¹. As the population ages, the survival rates of
47 ischemic heart disease improve, and more effective evidence-based therapies emerge,
48 the prevalence of heart failure continues to rise, affecting over 64 million individuals
49 globally². Despite ongoing efforts to treat and manage heart failure, there has been little
50 reduction in the burden of mortality and hospitalization³. Therefore, researching and
51 identifying modifiable risk factors is crucial for the management and prevention of
52 heart failure.

53 Heart failure is a complex clinical syndrome influenced by numerous factors, including
54 cardiomyopathy, activation of the sympathetic nervous system, abnormalities in energy
55 supply, cardiotoxic drugs, loss of cardiomyocytes, dysregulation of calcium handling,
56 and epigenetic mechanisms⁴⁻¹⁰. In addition to these factors, in recent years, there has
57 been an increasing recognition of the role of inflammation and the immune system in
58 the pathophysiology of heart failure. Following myocardial injury or infection, a
59 substantial influx of immune cells is recruited to the heart to clear dead tissues,

60 eliminate pathogens, and facilitate healing¹¹. Different subtypes of immune cells
61 participate in the inflammatory response, repair processes, and cardiac remodeling in
62 their unique ways, influencing the progression of heart failure. M2 macrophages, which
63 exhibit anti-inflammatory functions, are primarily activated by the inflammatory
64 cytokine IL-4. They mainly exert their effects by secreting anti-inflammatory cytokines
65 such as IL-10 to inhibit M1 macrophages, thereby improving the function of the
66 damaged heart and reducing cardiac fibrosis¹². Depletion of CD8+ T lymphocytes can
67 reduce apoptosis within ischemic myocardial tissue, hinder the inflammatory response,
68 limit myocardial damage, and improve cardiac function¹³. CD4+ T cells, on the other
69 hand, can modulate immune responses by secreting cytokines such as interferon-
70 gamma (IFN- γ) and tumor necrosis factor-alpha (TNF- α), which promote inflammation
71 and myocardial damage¹⁴. B cells are capable of regulating the heart's adaptation to
72 injury and ultimately influence the extent of cardiac functional impairment following
73 damage¹⁵. Regulatory T cells (Tregs) are beneficial to the heart as they suppress
74 excessive inflammatory responses in the early stages of heart damage and promote
75 stable scar formation. However, in chronic heart failure, the phenotype and function of
76 Tregs can shift towards a pro-fibrotic and anti-angiogenic cell type. This functional
77 transformation has rekindled interest¹⁶. Additionally, various subtypes of immune cells,
78 including neutrophils, dendritic cells, and NK cells, are involved to varying degrees in
79 the development of heart failure¹⁷⁻¹⁹. Despite mounting evidence indicating a close
80 connection between various subtypes of immune cells and heart failure, the outcomes
81 of attempts at new treatment strategies using immune modulation therapies have been
82 disappointing²⁰. Therefore, unraveling the complexity of the role played by the immune
83 system in heart failure, as well as its causal relationships, becomes critically important.
84 In this study, we will utilize five immune infiltration algorithms to uncover the quantity
85 of immune and stromal cells within the failing myocardium, illustrating the
86 myocardium's complex landscape of cellular heterogeneity. Moreover, through
87 Mendelian Randomization (MR) analysis, we will examine the intricate causal and
88 reverse causal relationships between 731 immune cell phenotypes of seven types of
89 immune cells and heart failure. Our research aims to shed new light on the role of

90 immune cells in the pathophysiology of heart failure and contribute to the development
 91 of immunomodulatory therapies. The outline of the design of our study was shown in
 92 Figure 1.



93
 94 *Figure 1: The study design.*

95
 96 **MATERIALS AND METHODS**

97 **Immune Infiltration Analysis**

98 To portray the intricate cell heterogeneity landscape of failing myocardium, we employ
 99 five immune infiltration algorithms: Cibersort, xCell, ssGSEA, MCPcounter, and
 100 QuanTIseq. The dataset we use is GSE57338, which consists of left ventricular
 101 myocardial samples from 95 patients with ischemic heart failure and 136 normal
 102 individuals. It represents the largest dataset of myocardial samples from heart failure
 103 patients currently available²¹. The Cibersort algorithm performs deconvolution analysis
 104 based on the principle of linear support vector regression, cataloging gene expression
 105 profiles of 22 types of immune cells. This includes seven types of T cells, naive and
 106 memory B cells, plasma cells, NK cells, and myeloid subsets²². The xCell algorithm
 107 employs ssGSEA to calculate enrichment scores for each cell type signature, enabling
 108 the assessment of infiltration levels for up to 64 cell types. This encompasses various

109 adaptive and innate immune cells, hematopoietic stem cells, epithelial cells, and
110 extracellular matrix cells²³. The ssGSEA algorithm calculates immune cell infiltration
111 based on markers for 24 types of immune cells provided by Bindea²⁴. The MCPcounter
112 algorithm uses a linear model to translate the expression levels of immune-related genes
113 into the abundance of eight immune cells and two stromal cells, including T cells, CD8+
114 T cells, cytotoxic lymphocytes, NK cells, B lymphocytes, monocytes, myeloid dendritic
115 cells, neutrophils, as well as endothelial cells and fibroblasts²⁵. The quanTIseq method
116 utilizes a deconvolution algorithm to predict the composition of various types of
117 immune cells within a sample, including 10 immune cell types such as B cells,
118 Monocytes, Neutrophils, Natural killer (NK) cells, and Non-regulatory CD4+ T cells²⁶.
119 Cell distribution differences between the heart failure group and the normal group are
120 compared using the t-test, with the threshold set at an adjusted p-value of less than 0.05.

121

122 MR Study design

123 In our study, we evaluated the causal relationships between 731 immune cell
124 phenotypes (grouped into 7 categories) and heart failure using bidirectional two-sample
125 Mendelian Randomization (MR) analysis. Our research adheres to the three core
126 assumptions of MR analysis: 1. Genetic variants must be strongly associated with the
127 exposure. 2. Genetic variants are uncorrelated with potential confounding factors. 3.
128 Genetic variants should only influence the outcome through the exposure and not
129 through other pathways²⁷. All data utilized in this study are publicly available and have
130 been obtained with the consent of the relevant participants and ethical approval, thus
131 institutional review board ethical approval was not required for this research.

132

133 Exposure and Outcome Data Acquisition

134 The GWAS catalog (GCST90001391 to GCST90002121) provides a summary of
135 GWAS statistical data for each immunological trait²⁸. It encompasses integrated data
136 collected from 3,757 individuals of European ancestry, covering 731 immune
137 phenotypes. As for the outcomes, we selected heart failure data from the HERMES
138 consortium, which includes 47,309 heart failure patients and 930,014 controls²⁹.

139

140 IVs selection

141 During the selection process for SNPs, we encountered challenges in identifying
142 effective SNPs due to the stringent genome-wide significance threshold ($P < 5E-8$)
143 applied in our GWAS screening. Consequently, we ultimately opted for a threshold
144 where SNP selection satisfied $P < 1E-5^{30}$. To prevent linkage disequilibrium (LD) from
145 affecting the analysis results, we set the LD threshold parameter r to 0.001 and used a
146 distance of 10,000 Kb for SNP analysis. Subsequently, we used the PhenoScanner V2
147 database, a human genotype-phenotype association repository, to further verify the
148 inclusion of SNP loci and to check for any other potential confounding variables
149 associated with the included SNP loci. Lastly, to assess whether the included SNPs were
150 affected by weak instrumental variables, we excluded values with an F-statistic greater
151 than 10 (calculated using the formula $F = \beta^2 / SE^2$, where β represents the allele
152 effect size, and SE is the standard error). If the F-statistic for SNPs is less than 10, it
153 indicates the possibility of a weak instrument variable bias with those SNPs, and
154 therefore, they are excluded to avoid affecting the results. Subsequently, we extract
155 outcome information through the IEU OpenGWAS database and ascertain the
156 relationships among SNPs that meet the assumed criteria from the results. By merging
157 the exposure data set with the generated data set and removing duplicate sequences, we
158 obtain eligible instrumental variables (IVs) that meet the standards for further analysis
159 to establish genetic associations.

160

161 Statistical analysis

162 In our study, Mendelian Randomization (MR) analysis was conducted using the
163 TwoSampleMR and MR-PRESSO packages within the R software, version 4.2.0. In
164 our primary analysis, the Inverse Variance Weighted (IVW) model was applied to assess
165 the causal relationship between each immune cell phenotype and the risk of heart failure
166 ³¹. The characteristic of the IVW method is that it does not consider the presence of an
167 intercept and uses the inverse of the final variance (the square of standard error) as the

168 weight for fitting. When using IVW to explore causal relationships, there may be other
169 factors affecting the bias estimation of genetic diversity and causal effects. MR-Egger
170 regression can detect horizontal pleiotropy through the p-value of the intercept. The
171 principle is to check whether the outcome effect is zero when the instrumental variable
172 effect is zero (i.e., whether the intercept is zero). If the intercept is not zero, it indicates
173 the existence of horizontal pleiotropy, which implies that the outcome exists even
174 without exposure³². The MR-PRESSO method is capable of detecting outlier SNPs and,
175 assuming that the SNPs utilized are valid, provides a causal estimate after the potential
176 outliers are removed³³. Due to the diversity of study subjects and experimental
177 conditions, two-sample Mendelian Randomization (MR) analysis may exhibit
178 heterogeneity, leading to a potential bias in the estimation of causal effects. We
179 primarily assess heterogeneity using Cochran's Q statistic, with a p-value less than 0.05
180 indicating significant heterogeneity. When using the random-effects IVW as the
181 primary outcome measure, heterogeneity is considered acceptable. If the p-value is
182 greater than 0.05 in the test, there is no evidence of heterogeneity among the included
183 instrumental variables (IVs), meaning that the impact of heterogeneity on the causal
184 effect estimation can be ignored. Finally, to evaluate the influence of individual SNPs
185 on the overall estimate, a "leave-one-out" analysis is conducted by sequentially
186 excluding each SNP from the analysis. The leave-one-out sensitivity test calculates the
187 MR results of the remaining IVs after each IV is removed one by one. If the MR results
188 estimated by the other IVs differ significantly from the overall result after the exclusion
189 of a particular IV, this indicates that the MR results are sensitive to that IV. If there is
190 no significant change in the overall results, the results are considered reliable. All results
191 are presented as odds ratios (OR) with 95% confidence intervals (CI), and when $p < 0.05$,
192 the results are considered to be statistically significant.


193

194 **RESULTS**

195 Immune Infiltration Analysis of Myocardium

196 We conducted an immune infiltration analysis on the dataset GSE57338 utilizing five
197 immunoinfiltration algorithms: Cibersort, xCell, ssGSEA, MCPcounter, and

198 QuantIseq. According to the Cibersort algorithm, differences were observed in 6
 199 immune cell types. The xCell algorithm indicated differences in 24 cell types. The
 200 ssGSEA algorithm revealed discrepancies in 15 immune cell types. The MCPcounter
 201 algorithm showed variances in 2 immune cells and 1 stromal cell type. The QuantIseq
 202 algorithm demonstrated differences in 6 immune cell types. The results of the analysis
 203 and cell expression are displayed in Figure 2.




204

205 *Figure 6: Immune cell infiltration analysis between HF and control. (A) Result of*
 206 *Cibersort algorithm. (B) Result of MCPcounter algorithm. (C) Result of QuantIseq*
 207 *algorithm. (D) Result of ssGSEA algorithm. (E) Result of xCell algorithm.*

208

209 Effect of Immunocyte on HF

210 We conducted instrumental variable (IV) selection on GWAS data for 731 immune cell
211 phenotypes, with all IVs having F values greater than 10, indicating no presence of
212 weak instrument bias. The results from the Inverse Variance Weighted (IVW) method
213 predicting genetic instruments for immune cell phenotypes with causal relationships to
214 heart failure are shown in Figure 3. Our analysis indicates that 19 immune cell
215 phenotypes across 5 immune cell groups are associated with an increased risk of heart
216 failure ($OR > 1$, $P < 0.05$). Specifically, B cell phenotypes include: CD19 on IgD+, IgD+
217 AC, IgD on IgD+ CD38dim, CD27 on IgD- CD38dim, IgD on IgD+ CD24+, CD27 on
218 IgD- CD38-, IgD+ CD38br AC, CD38 on IgD+ CD38br, CD19 on IgD+ CD38br, Sw
219 mem %lymphocyte, and BAFF-R on IgD- CD38dim. cDC phenotype: CCR2 on
220 CD62L+ myeloid DC. Myeloid cell phenotype: CD45 on lymphocyte. TBNK
221 phenotype: TCRgd %lymphocyte. Treg phenotypes include: CD28+ CD45RA+
222 CD8br %T cell, CD28+ CD45RA+ CD8br AC, CD39+ CD8br %CD8br, CD28-
223 CD127- CD25++ CD8br %CD8br, and CD28- CD127- CD25++ CD8br %T cell. There
224 are 12 immune cell phenotypes across 6 immune cell groups that are associated with a
225 decreased risk of heart failure ($OR < 1$, $P < 0.05$). Specifically, B cell phenotypes include:
226 CD20 on IgD+ CD38br, Unsw Mem %lymphocyte, BAFF-R on IgD+ CD38br, and
227 CD20 on IgD- CD38dim. cDC phenotype: CD62L- DC %DC. Maturation stages of T
228 cell phenotype: HVEM on TD CD4+. Myeloid cell phenotype: CD11b on CD14+
229 monocyte. TBNK phenotypes include: HLA DR++ monocyte %leukocyte, SSC-A on
230 HLA DR+ NK, SSC-A on CD14+ monocyte, and CD45 on CD8br. Treg phenotype:
231 Activated Treg AC. Results for all analytical methods are provided in Supplementary
232 File 1.



233

234 *Figure 3: Associations between immune cell phenotypes and risk of heart failure.*

235

236 Sensitivity Analysis of the Effect of Immunocyte on HF

237 The sensitivity analysis results indicate that the immune cell phenotypes used for MR
 238 analysis in heart failure do not present evidence of heterogeneity (Q test $P > 0.05$),
 239 horizontal pleiotropy (MR-Egger intercept method $P > 0.05$), or significant outliers,
 240 suggesting that our findings are robust and credible. The "leave-one-out" analysis
 241 reveals that sequentially excluding each single nucleotide polymorphism (SNP) yields
 242 results from the remaining SNPs' IVW analysis that are consistent with the outcomes
 243 obtained when all SNPs are included, therefore indicating that no single SNP has a
 244 substantial effect on the estimated causal association. The results of heterogeneity and
 245 pleiotropy analysis are shown in Supplementary file 2.

246

247 Effect of HF on Immunocyte

248 We performed IV selection on the GWAS data for HF, ensuring that all IVs had an F
249 statistic greater than 10 to avoid weak instrument bias. Unfortunately, our MR analysis
250 did not uncover any causal relationships between HF and the 731 immune cell
251 phenotypes examined. As such, we found no bidirectional causality between immune
252 cell phenotypes and heart failure.

253

254 **DISCUSSION**

255 In our study, we initially employed five different immune infiltration analysis
256 algorithms to assess the complex cellular heterogeneity within the failing myocardium.
257 Despite variations in the underlying logic and weights of the different immune
258 infiltration analysis algorithms, all five methods consistently indicated an upregulated
259 expression of T cells or their subgroups in the failing myocardium as compared to
260 normal myocardium. Additionally, at least two of these algorithms support the presence
261 of differences in Mast cells, B cells, NK cells, and macrophages within the failing
262 myocardium. Hence, the results of our immune infiltration analysis suggest alterations
263 in certain immune cell levels in the failing myocardium when contrasted with normal
264 myocardium.

265 In order to investigate whether the altered levels of immune cells are causally associated
266 with the onset and progression of HF, we systematically provided genetic support for
267 the causal relationship between 731 immune cell phenotypes across seven groups of
268 immune cells and HF through bidirectional MR analysis. We observed a causal
269 relationship between 31 immune cell phenotypes in B cells, cDC, TBNK, Treg,
270 Myeloid cells and Maturation stages of T cells with HF in forward MR. In contrast, in
271 reverse MR, there was no evidence to support a causal relationship between HF and
272 731 immune cell phenotypes. There was no bidirectional causality between HF and 731
273 immune cell phenotypes. As the results of the reverse MR analysis do not support a
274 causal relationship between HF and immune cells, this suggests that the changes in
275 immune cell levels observed in the failing myocardium are not caused by heart failure
276 itself. Although the reasons for these alterations in immune cell expression are not yet

277 clear, they may have an impact on the progression of heart failure.

278 The results of the immune infiltration analysis indicate an increased expression of T
279 cells and their subgroups in the failing myocardium. However, the MR analysis reveals
280 that the impact of different immune phenotypes within T cell subgroups, such as CD4
281 or CD8, on heart failure is complex, which may account for the discouraging outcomes
282 of immune modulatory therapies. Alba Vilella-Figuerola et al. demonstrated that
283 activated CD45+ T cells were positively correlated with the severity of congestive HF,
284 which was consistent with our MR analysis of CD45 on lymphocyte positively
285 correlated with HF³⁴. Elisa Martini et al. focused their research on CD45+ cells and
286 found that activated immune cells were strongly associated with HF³⁵. Yun-Long Zhang
287 et al. concluded that targeting CD11b was associated with cardiac remodeling and may
288 benefit HF³⁶. Animal studies have demonstrated that the systemic activation of induced
289 regulatory T cells can be employed in anti-remodeling therapy for the repair of ischemic
290 tissues³⁷. The expression of CD69 on regulatory T cells can also protect against immune
291 injury post-myocardial infarction, thereby preventing heart failure³⁸. Furthermore,
292 research has indicated that cardiac fibroblasts expressing xenogeneic antigens can be
293 effectively targeted and eliminated through the adoptive transfer of antigen-specific
294 CD8+ T cells, which may alleviate myocardial fibrosis³⁹. Therefore,
295 immunomodulatory therapies that intervene with T cells are promising, but it is
296 important to consider the regulation of specific subgroups⁴⁰.

297 MR results identified 16 immune cell phenotypes in B cells that were significantly
298 associated with HF. B cells are a key part of the organism's immune system,
299 participating in the immune response through the production of antibodies, as well as
300 in regulating the activities of other immune cells⁴¹. B cells regulate macrophage
301 phenotype in the myocardium and play an important role in maintaining myocardial
302 homeostasis⁴². Several studies have shown that B cells can influence cardiac
303 remodeling and inflammatory responses after myocardial infarction, thereby mediating
304 HF^{43,44}. In addition, antibodies may also mediate myocardial injury through
305 complement-associated mechanisms and may interact with cardiomyocytes or other
306 immune cells to affect myocardial function⁴⁵⁻⁴⁷. Andrea M. Cordero-Reyes et al.

307 concluded that pathways of B cell activation were intimately involved in the
308 progression of HF⁴⁸.

309 MR results identified 5 immune cell phenotypes in TBNK cells that were significantly
310 associated with HF. Existing studies suggest that natural killer (NK) cells contribute to
311 the mitigation of cardiac inflammation and fibrosis by inhibiting the infiltration of
312 eosinophils, thereby exerting an anti-heart failure effect⁴⁹. Additionally, NK cells may
313 offer protective benefits in the aftermath of a heart attack by boosting the expression of
314 cardioprotective cytokines, including IL-10, which aids in the remodeling and
315 preservation of left ventricular function⁵⁰. In a contradiction, findings derived from the
316 xCell algorithm indicate a reduction in NK cell expression within failing myocardial
317 tissue, which is at odds with the results yielded by the ssGSEA and QuanTIseq
318 algorithms. This is further complicated by a clinical study involving 82 patients with
319 end-stage heart failure, which revealed that the levels of circulating NK cells in patients
320 were lower compared to healthy individuals⁵¹.

321 Our study also identified certain immune cell phenotypes that exhibit causal
322 relationships with HF, yet to date, there have been no clinical studies or reports on their
323 association with HF. The role of these immune cell phenotypes in the pathogenesis of
324 heart failure holds promise and warrants further investigation. Additionally, our
325 bidirectional Mendelian randomization does not support a causal relationship between
326 HF and 731 immune cell phenotypes. This suggests that certain immune cell
327 phenotypes that could potentially ameliorate or accelerate the course of heart failure are
328 not influenced by the progression of the condition.

329 In this study, we initially confirmed the levels of immune cells in failing myocardium
330 using five distinct immune infiltration analysis algorithms. Subsequently, a two-sample
331 bidirectional MR analysis was performed, which allowed for large sample sizes and
332 high statistical efficiency. The conclusions of the MR analysis in this research are based
333 on exploring the causal relationship between the two variables with genetic
334 instrumental variables, and causal inference and result verification were carried out
335 using various MR analysis methods. Therefore, the results are robust and not affected
336 or confounded by pleiotropy at horizontal levels.

337 However, our study should consider some limitations. Firstly, due to the differing logic
338 and weights of the immune infiltration analysis algorithms used, there are
339 inconsistencies in the computed results, which require further experimental support.
340 Secondly, we selected IVs with a P-value threshold of $P < 1E-5$, therefore, the strength
341 of the associations of these IVs may not be robust, despite allowing for a more
342 comprehensive assessment of the association between immune cell phenotypes and
343 heart failure. Thirdly, as this study is based on a European population, the applicability
344 of the results to other ethnic groups remains debatable, limiting the breadth of our
345 results. Additionally, despite multiple sensitivity analyses, the assessment of horizontal
346 pleiotropy remains limited. While statistically it is considered satisfactory to eliminate
347 heterogeneity and horizontal pleiotropy, it cannot be fully guaranteed that such factors
348 are absent in the clinical environment. Finally, comprehensive clinical trials are needed
349 to draw clinical conclusions. Therefore, to elucidate the association and mechanisms
350 between individual immune cell phenotypes and heart failure, we need more extensive
351 GEO and GWAS databases, as well as further analytical methods or experimental
352 validations.

353

354 **CONCLUSION**

355 We determined the levels of immune cells in failing myocardium using five immune
356 infiltration analysis algorithms and demonstrated the causal relationships between
357 various immune cell phenotypes and heart failure through comprehensive bidirectional
358 two-sample MR analysis. This opens new avenues for researchers to explore the
359 biological mechanisms of heart failure. More importantly, it offers innovative
360 perspectives for investigating immunocyte therapies for heart failure, which may aid in
361 the prevention and treatment of heart failure.

362

363

364 **Acknowledgements**

365 Not applicable.

366

367 **CRedit authorship contribution statement**

368 Yiding Yu: Conceptualization, Methodology, Validation, Formal analysis,

369 Investigation, Resources, Visualization, Writing – original draft, Writing – review &

370 editing. Huajing Yuan: Methodology, Validation, Formal analysis, Software, Data

371 curation, Writing – original draft. Wenwen Liu: Software, Data curation, Writing –

372 review & editing. Yitao Xue: Supervision, Funding acquisition, Writing – review &

373 editing. Xiujuan Liu: Project administration, Supervision, Writing – review & editing.

374 Wangjun Hou: Project administration, Writing – review & editing, Funding

375 acquisition. Yan Li: Project administration, Writing – review & editing, Funding

376 acquisition.

377

378 **Consent for publication**

379 Not applicable.

380

381 **Competing interests**

382 The authors have no conflict of interest to disclose.

383

384 **Ethics approval and consent to participate**

385 Not applicable.

386

387 **Funding**

388 Our work was supported by the Natural Science Foundation of Shandong Province (CN)

389 [Grant Nos.ZR2023MH053] and National Natural Science Foundation of China [Grant

390 Nos. 81774247 and 81804045].

391

392 **Availability of data and materials**

393 Publicly available datasets were analyzed in this study. This data can be found here:

394 GSE57338 and GWAS Catalog ([https://www.ebi.ac.uk/gwas/downloads/summary-](https://www.ebi.ac.uk/gwas/downloads/summary-statistics)
395 [statistics](https://www.ebi.ac.uk/gwas/downloads/summary-statistics))

396

397

398

399

400

401 **REFERENCES**

402 1. S.A. Hunt, W.T. Abraham, M.H. Chin, A.M. Feldman, G.S. Francis, T.G.
403 Ganiats, M. Jessup, M.A. Konstam, D.M. Mancini, K. Michl, J.A. Oates, P.S.
404 Rahko, M.A. Silver, L.W. Stevenson, C.W. Yancy, E.M. Antman, S.C. Smith Jr., C.D.
405 Adams, J.L. Anderson, D.P. Faxon, V. Fuster, J.L. Halperin, L.F. Hiratzka, S.A.
406 Hunt, A.K. Jacobs, R. Nishimura, J.P. Ornato, R.L. Page, B. Riegel, *Acc/aha 2005*
407 *guideline update for the diagnosis and management of chronic heart failure in the adult*
408 *summary article, J. Am. Coll. Cardiol.* 46 (2005) 1116–1143,
409 <https://doi.org/10.1016/j.jacc.2005.08.023>.

410 2. Savarese, G., Becher, P. M., Lund, L. H., Seferovic, P., Rosano, G. M. C., & Coats,
411 A. J. S. (2023). Global burden of heart failure: a comprehensive and updated review of
412 epidemiology. *Cardiovascular research*, 118(17), 3272–3287.
413 <https://doi.org/10.1093/cvr/cvac013>

414 3. Roger V. L. (2021). Epidemiology of Heart Failure: A Contemporary Perspective.
415 *Circulation research*, 128(10), 1421–1434.
416 <https://doi.org/10.1161/CIRCRESAHA.121.318172>

417 4. Towbin, J., & Bowles, N. (2002). The failing heart. *Nature*, 415, 227–233.

418 <https://doi.org/10.1038/415227a>.

419 5. Lympelopoulos, A., Rengo, G., & Koch, W. (2013). Adrenergic Nervous System
420 in Heart Failure: Pathophysiology and Therapy. *Circulation Research*, 113, 739–753.

421 <https://doi.org/10.1161/CIRCRESAHA.113.300308>.

422 6. Ventura-clapier, R., Garnier, A., & Veksler, V. (2004). Energy metabolism in heart
423 failure. *The Journal of Physiology*, 555. <https://doi.org/10.1113/jphysiol.2003.055095>.

424 7. Kemp, C., & Conte, J. (2012). The pathophysiology of heart failure..
425 *Cardiovascular pathology : the official journal of the Society for Cardiovascular*
426 *Pathology*, 21 5, 365-71 . <https://doi.org/10.1016/j.carpath.2011.11.007>.

427 8. Slørdal, L., & Spigset, O. (2006). Heart Failure Induced by Non-Cardiac Drugs.
428 *Drug Safety*, 29, 567-586. <https://doi.org/10.2165/00002018-200629070-00003>.

429 9. Oka, T., & Komuro, I. (2008). Molecular mechanisms underlying the transition of
430 cardiac hypertrophy to heart failure.. *Circulation journal : official journal of the*
431 *Japanese Circulation Society*, 72 Suppl A, A13-6 . [https://doi.org/10.1253/CIRCJ.CJ-](https://doi.org/10.1253/CIRCJ.CJ-08-0481)
432 08-0481.

433 10. Papait, R., Greco, C., Kunderfranco, P., Latronico, M., & Condorelli, G. (2013).
434 Epigenetics: a new mechanism of regulation of heart failure?. *Basic Research in*
435 *Cardiology*, 108. <https://doi.org/10.1007/s00395-013-0361-1>.

436 11. Swirski, F., & Nahrendorf, M. (2018). Cardioimmunology: the immune system in
437 cardiac homeostasis and disease. *Nature Reviews Immunology*, 18, 733 - 744.
438 <https://doi.org/10.1038/s41577-018-0065-8>.

439 12. Peet, C., Ivetic, A., Bromage, D. I., & Shah, A. M. (2020). Cardiac monocytes and
440 macrophages after myocardial infarction. *Cardiovascular research*, 116(6), 1101–1112.
441 <https://doi.org/10.1093/cvr/cvz336>

442 13. Santos-Zas, I., Lemarié, J., Zlatanova, I., Cachanado, M., Seghezzi, J. C., Benamer,
443 H., Goube, P., Vandestienne, M., Cohen, R., Ezzo, M., Duval, V., Zhang, Y., Su, J. B.,
444 Bizé, A., Sambin, L., Bonnin, P., Branchereau, M., Heymes, C., Tanchot, C., Vilar, J., ...
445 Ait-Oufella, H. (2021). Cytotoxic CD8+ T cells promote granzyme B-dependent
446 adverse post-ischemic cardiac remodeling. *Nature communications*, 12(1), 1483.
447 <https://doi.org/10.1038/s41467-021-21737-9>

- 448 14. Vdovenko, D., & Eriksson, U. (2018). Regulatory Role of CD4⁺ T Cells in
449 Myocarditis. *Journal of immunology research*, 2018, 4396351.
450 <https://doi.org/10.1155/2018/4396351>
- 451 15. Bermea, K., Bhalodia, A., Huff, A., Rousseau, S., & Adamo, L. (2022). The Role
452 of B Cells in Cardiomyopathy and Heart Failure. *Current cardiology reports*, 24(8),
453 935–946. <https://doi.org/10.1007/s11886-022-01722-4>
- 454 16. Lu, Y., Xia, N., & Cheng, X. (2021). Regulatory T Cells in Chronic Heart Failure.
455 *Frontiers in immunology*, 12, 732794. <https://doi.org/10.3389/fimmu.2021.732794>
- 456 17. Tang, X., Wang, P., Zhang, R., Watanabe, I., Chang, E., Vinayachandran, V., Nayak,
457 L., Lapping, S., Liao, S., Madera, A., Sweet, D. R., Luo, J., Fei, J., Jeong, H. W., Adams,
458 R. H., Zhang, T., Liao, X., & Jain, M. K. (2022). KLF2 regulates neutrophil activation
459 and thrombosis in cardiac hypertrophy and heart failure progression. *The Journal of*
460 *clinical investigation*, 132(3), e147191. <https://doi.org/10.1172/JCI147191>
- 461 18. Saleh, D., Jones, R. T. L., Schroth, S. L., Thorp, E. B., & Feinstein, M. J. (2023).
462 Emerging Roles for Dendritic Cells in Heart Failure. *Biomolecules*, 13(10), 1535.
463 <https://doi.org/10.3390/biom13101535>
- 464 19. Ong, S., Rose, N., & Čiháková, D. (2017). Natural killer cells in inflammatory
465 heart disease.. *Clinical immunology*, 175, 26-33 .
466 <https://doi.org/10.1016/j.clim.2016.11.010>.
- 467 20. Fildes, J. E., Shaw, S. M., Yonan, N., & Williams, S. G. (2009). The immune system
468 and chronic heart failure: is the heart in control?. *Journal of the American College of*
469 *Cardiology*, 53(12), 1013–1020. <https://doi.org/10.1016/j.jacc.2008.11.046>
- 470 21. Liu, Y., Morley, M., Brandimarto, J., Hannenhalli, S., Hu, Y., Ashley, E. A., Tang,
471 W. H., Moravec, C. S., Margulies, K. B., Cappola, T. P., Li, M., & MAGNet consortium
472 (2015). RNA-Seq identifies novel myocardial gene expression signatures of heart
473 failure. *Genomics*, 105(2), 83–89. <https://doi.org/10.1016/j.ygeno.2014.12.002>
- 474 22. Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang,
475 C. D., Diehn, M., & Alizadeh, A. A. (2015). Robust enumeration of cell subsets from
476 tissue expression profiles. *Nature methods*, 12(5), 453–457.
477 <https://doi.org/10.1038/nmeth.3337>

- 478 23. Aran, D., Hu, Z., & Butte, A. J. (2017). xCell: digitally portraying the tissue cellular
479 heterogeneity landscape. *Genome biology*, 18(1), 220. [https://doi.org/10.1186/s13059-](https://doi.org/10.1186/s13059-017-1349-1)
480 017-1349-1
- 481 24. Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C.,
482 Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., Bruneval, P., Fridman, W. H.,
483 Becker, C., Pagès, F., Speicher, M. R., Trajanoski, Z., & Galon, J. (2013).
484 Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape
485 in human cancer. *Immunity*, 39(4), 782–795.
486 <https://doi.org/10.1016/j.immuni.2013.10.003>
- 487 25. Becht, E., Giraldo, N. A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves,
488 J., Laurent-Puig, P., Sautès-Fridman, C., Fridman, W. H., & de Reyniès, A. (2016).
489 Estimating the population abundance of tissue-infiltrating immune and stromal cell
490 populations using gene expression. *Genome biology*, 17(1), 218.
491 <https://doi.org/10.1186/s13059-016-1070-5>
- 492 26. Finotello, F., Mayer, C., Plattner, C., Laschober, G., Rieder, D., Hackl, H.,
493 Krogdham, A., Loncova, Z., Posch, W., Wilflingseder, D., Sopper, S., Ijsselsteijn, M.,
494 Brouwer, T. P., Johnson, D., Xu, Y., Wang, Y., Sanders, M. E., Estrada, M. V., Ericsson-
495 Gonzalez, P., Charoentong, P., ... Trajanoski, Z. (2019). Molecular and
496 pharmacological modulators of the tumor immune contexture revealed by
497 deconvolution of RNA-seq data. *Genome medicine*, 11(1), 34.
498 <https://doi.org/10.1186/s13073-019-0638-6>
- 499 27. Bowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016). Consistent
500 Estimation in Mendelian Randomization with Some Invalid Instruments Using a
501 Weighted Median Estimator. *Genetic epidemiology*, 40(4), 304–314.
502 <https://doi.org/10.1002/gepi.21965>
- 503 28. Orrù, V., Steri, M., Sidore, C., Marongiu, M., Serra, V., Olla, S., Sole, G., Lai, S.,
504 Dei, M., Mulas, A., Viridis, F., Piras, M. G., Lobina, M., Marongiu, M., Pitzalis, M.,
505 Deidda, F., Loizedda, A., Onano, S., Zoledziewska, M., Sawcer, S., ... Cucca, F. (2020).
506 Complex genetic signatures in immune cells underlie autoimmunity and inform therapy.
507 *Nature genetics*, 52(10), 1036–1045. <https://doi.org/10.1038/s41588-020-0684-4>

- 508 29. Shah, S., Henry, A., Roselli, C., Lin, H., Sveinbjörnsson, G., Fatemifar, G.,
509 Hedman, Å. K., Wilk, J. B., Morley, M. P., Chaffin, M. D., Helgadottir, A., Verweij, N.,
510 Dehghan, A., Almgren, P., Andersson, C., Aragam, K. G., Ärnlöv, J., Backman, J. D.,
511 Biggs, M. L., Bloom, H. L., ... Lumbers, R. T. (2020). Genome-wide association and
512 Mendelian randomisation analysis provide insights into the pathogenesis of heart
513 failure. *Nature communications*, 11(1), 163. [https://doi.org/10.1038/s41467-019-](https://doi.org/10.1038/s41467-019-13690-5)
514 13690-5
- 515 30. Li, P., Wang, H., Guo, L., Gou, X., Chen, G., Lin, D., Fan, D., Guo, X., & Liu, Z.
516 (2022). Association between gut microbiota and preeclampsia-eclampsia: a two-sample
517 Mendelian randomization study. *BMC medicine*, 20(1), 443.
518 <https://doi.org/10.1186/s12916-022-02657-x>
- 519 31. Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., Laurin,
520 C., Burgess, S., Bowden, J., Langdon, R., Tan, V. Y., Yarmolinsky, J., Shihab, H. A.,
521 Timpson, N. J., Evans, D. M., Relton, C., Martin, R. M., Davey Smith, G., Gaunt, T. R.,
522 & Haycock, P. C. (2018). The MR-Base platform supports systematic causal inference
523 across the human phenome. *eLife*, 7, e34408. <https://doi.org/10.7554/eLife.34408>
- 524 32. Bowden, J., Davey Smith, G., & Burgess, S. (2015). Mendelian randomization with
525 invalid instruments: effect estimation and bias detection through Egger regression.
526 *International journal of epidemiology*, 44(2), 512–525.
527 <https://doi.org/10.1093/ije/dyv080>
- 528 33. Verbanck, M., Chen, C. Y., Neale, B., & Do, R. (2018). Detection of widespread
529 horizontal pleiotropy in causal relationships inferred from Mendelian randomization
530 between complex traits and diseases. *Nature genetics*, 50(5), 693–698.
531 <https://doi.org/10.1038/s41588-018-0099-7>
- 532 34. Vilella-Figuerola A, Padro T, Roig E, Mirabet S, Badimon L. New factors in heart
533 failure pathophysiology: Immunity cells release of extracellular vesicles. *Front*
534 *Cardiovasc Med* (2022) 9: 939625. doi:10.3389/fcvm.2022.939625
- 535 35. Martini E, Kunderfranco P, Peano C, Carullo P, Cremonesi M, Schorn T, et al.
536 Single-Cell Sequencing of Mouse Heart Immune Infiltrate in Pressure Overload-Driven
537 Heart Failure Reveals Extent of Immune Activation. *Circulation* (2019) 140: 2089-107.

538 doi:10.1161/CIRCULATIONAHA.119.041694

539 36. Zhang YL, Bai J, Yu WJ, Lin QY, Li HH. CD11b mediates hypertensive cardiac
540 remodeling by regulating macrophage infiltration and polarization. *J Adv Res* (2024)

541 55: 17-31. doi:10.1016/j.jare.2023.02.010

542 37. Choo EH, Lee JH, Park EH, Park HE, Jung NC, Kim TH, Koh YS, Kim E, Seung
543 KB, Park C, Hong KS, Kang K, Song JY, Seo HG, Lim DS, Chang K. Infarcted
544 Myocardium-Primed Dendritic Cells Improve Remodeling and Cardiac Function After

545 Myocardial Infarction by Modulating the Regulatory T Cell and Macrophage
546 Polarization. *Circulation*. 2017 Apr 11;135(15):1444-1457. doi:
547 10.1161/CIRCULATIONAHA.116.023106.

548 38. Blanco-Domínguez R, de la Fuente H, Rodríguez C, Martín-Aguado L, Sánchez-
549 Díaz R, Jiménez-Alejandro R, Rodríguez-Arabaolaza I, Curtabbi A, García-Guimaraes

550 MM, Vera A, Rivero F, Cuesta J, Jiménez-Borreguero LJ, Cecconi A, Duran-Cambra A,
551 Taurón M, Alonso J, Bueno H, Villalba-Orero M, Enríquez JA, Robson SC, Alfonso F,

552 Sánchez-Madrid F, Martínez-González J, Martín P. CD69 expression on regulatory T
553 cells protects from immune damage after myocardial infarction. *J Clin Invest*. 2022
554 Nov 1;132(21):e152418. doi: 10.1172/JCI152418.

555 39. Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J,
556 Monslow J, Lo A, Han W, Wang T, Bedi K, Morley MP, Linares Saldana RA, Bolar NA,

557 McDaid K, Assenmacher CA, Smith CL, Wirth D, June CH, Margulies KB, Jain R,
558 Puré E, Albelda SM, Epstein JA. Targeting cardiac fibrosis with engineered T cells.

559 *Nature*. 2019 Sep;573(7774):430-433. doi: 10.1038/s41586-019-1546-z.

560 40. Lu Y, Xia N, Cheng X. Regulatory T Cells in Chronic Heart Failure. *Front Immunol*.
561 2021 Sep 22;12:732794. doi: 10.3389/fimmu.2021.732794.

562 41. Bermea K, Bhalodia A, Huff A, Rousseau S, Adamo L. The Role of B Cells in
563 Cardiomyopathy and Heart Failure. *Curr Cardiol Rep* (2022) 24: 935-46.

564 doi:10.1007/s11886-022-01722-4

565 42. Rocha-Resende C, Pani F, Adamo L. B cells modulate the expression of MHC-II
566 on cardiac CCR2(-) macrophages. *J Mol Cell Cardiol* (2021) 157: 98-103.

567 doi:10.1016/j.yjmcc.2021.05.003

- 568 43. Heinrichs M, Ashour D, Siegel J, Buchner L, Wedekind G, Heinze KG, et al. The
569 healing myocardium mobilizes a distinct B-cell subset through a CXCL13-CXCR5-
570 dependent mechanism. *Cardiovasc Res* (2021) 117: 2664-76. doi:10.1093/cvr/cvab181
- 571 44. Yan X, Anzai A, Katsumata Y, Matsushashi T, Ito K, Endo J, et al. Temporal
572 dynamics of cardiac immune cell accumulation following acute myocardial infarction.
573 *J Mol Cell Cardiol* (2013) 62: 24-35. doi:10.1016/j.yjmcc.2013.04.023
- 574 45. Zhang M, Michael LH, Grosjean SA, Kelly RA, Carroll MC, Entman ML. The role
575 of natural IgM in myocardial ischemia-reperfusion injury. *J Mol Cell Cardiol* (2006)
576 41: 62-67. doi:10.1016/j.yjmcc.2006.02.006
- 577 46. Ludwig RJ, Vanhoorelbeke K, Leypoldt F, Kaya Z, Bieber K, McLachlan SM, et
578 al. Mechanisms of Autoantibody-Induced Pathology. *Front Immunol* (2017) 8: 603.
579 doi:10.3389/fimmu.2017.00603
- 580 47. Haudek SB, Trial J, Xia Y, Gupta D, Pilling D, Entman ML. Fc receptor
581 engagement mediates differentiation of cardiac fibroblast precursor cells. *Proc Natl*
582 *Acad Sci U S A* (2008) 105: 10179-84. doi:10.1073/pnas.0804910105
- 583 48. Cordero-Reyes AM, Youker KA, Torre-Amione G. The role of B-cells in heart
584 failure. *Methodist Debaquey Cardiovasc J* (2013) 9: 15-19. doi:10.14797/mdcj-9-1-15
- 585 49. Ong S, Ligons DL, Barin JG, Wu L, Talor MV, Diny N, Fontes JA, Gebremariam
586 E, Kass DA, Rose NR, Čiháková D. Natural killer cells limit cardiac inflammation and
587 fibrosis by halting eosinophil infiltration. *Am J Pathol*. 2015 Mar;185(3):847-61. doi:
588 10.1016/j.ajpath.2014.11.023.
- 589 50. Sobirin MA, Kinugawa S, Takahashi M, Fukushima A, Homma T, Ono T,
590 Hirabayashi K, Suga T, Azalia P, Takada S, Taniguchi M, Nakayama T, Ishimori N,
591 Iwabuchi K, Tsutsui H. Activation of natural killer T cells ameliorates postinfarct
592 cardiac remodeling and failure in mice. *Circ Res*. 2012 Sep 28;111(8):1037-47. doi:
593 10.1161/CIRCRESAHA.112.270132.
- 594 51. Vredevoe DL, Widawski M, Fonarow GC, Hamilton M, Martínez-Maza O, Gage
595 JR. Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy
596 in heart failure. *Am J Cardiol*. 2004 Apr 15;93(8):1007-11. doi:
597 10.1016/j.amjcard.2003.12.054.

598

599

600

601

602

603

604

605

606

607

608

609

610